The skin gateway
to the Immune System

DBV Technologies introduces its new Chief Financial Officer

DBV Technologies proudly welcomes Mr. David Schilansky as its new Chief Financial Officer

Download official press release (109.4 KB)

Bagneux, December 6, 2011 - DBV Technologies announces the arrival of David Schilansky – starting December 19 - as Chief Financial Officer and as such, will supervise all financial activities of the company as well as partnerships and Business Development initiatives. David will be a member of the Executive Committee.

"The integration of David Schilansky to DBV's management team will allow the company to pursue its structuration and improve its governance. It allows furthermore, for DBV to set itself into gear for the next essential development steps that will take place during 2012. The arrival of David brings an essential contribution to the company at a time when DBV Technologies wants to give a new impulse to its development in Europe and in the United States" has said Pierre-Henri Benhamou, CEO of DBV Technologies.

Prior to joining DBV Technologies, David Schilansky was Deputy CFO of Ipsen, that he joined in 2006. David has held important positions within the Finance & Administrative Department, and participated in several external growth transactions as well as the creation of an Investor Relations Department. In 2011, David also served as interim CFO and member of the Executive Committee. Prior to joining Ipsen, David spent three years at UBS Warburg, in Mergers & Acquisitions, and three years at Thomson as Investor Relations’ Officer. David graduated both from Paris Dauphine University and the Imperial College London.

Dernières news :
  • Jan, 31 2012 - DBV Technologies announces the filing of its “Document de Base” with the French Autorité des marchés financiers (the “AMF”) for proposed Initial Public Offering on the regulated market of NYSE Euronext in Paris More
  • Dec, 06 2011 - DBV Technologies proudly welcomes Mr. David Schilansky as its new Chief Financial Officer More
  • Sep, 21 2011 - DBV Technologies moves into new buildings to meet its growth and international development needs More
  • May, 17 2011 - DBV demonstrates ability of VIASKIN® to administer allergen via intact skin by targeting dendritic cells for safe treatment of allergic disease
    More

Legal Mention

CNIL number: 1544201 v 0

DBV technologies - siège social
Green Square - Bâtiment D
80/84 rue des Meuniers
92220 Bagneux
France
Phone: +33 (0)1 55 42 78 78
Fax: +33 (0)1 43 26 10 83

SIRET: 441772522 00013
RCS: Nanterrre

Executive editor: Pierre-Henri Benhamou

Hosting service: OVH www.ovh.com

Design : l’enchanteur www.lenchanteur.com

Contact